

Table S2. SUCRA and probability of each drug for the different variables studied in the NMA

a) Monotherapy

| | EASI 75 | | IGA 0/1 | | EASI 90 | | NRS P | | ANY AE | | UPPER TRACT INFECTION | | SEVERE AE | | WITHDRAWN | |
|-------------|---------|-----------|---------|-----------|---------|-----------|-------|-----------|--------|---------|-----------------------|---------|-----------|---------|-----------|---------|
| | SUCRA | Prob Best | SUCRA | Prob Best | SUCRA | Prob Best | SUCRA | Prob Best | SUCRA | Prob AE | SUCRA | Prob AE | SUCRA | Prob AE | SUCRA | Prob AE |
| ABRO100 | 0.55 | 0.00 | 0.50 | 0.00 | 0.42 | 0.00 | 0.35 | 0.00 | 0.71 | 0.04 | 0.58 | 0.10 | 0.64 | 0.08 | 0.17 | 0.00 |
| ABRO200 | 0.85 | 0.06 | 0.77 | 0.01 | 0.76 | 0.03 | 0.69 | 0.02 | 0.91 | 0.48 | 0.36 | 0.02 | 0.73 | 0.18 | 0.15 | 0.00 |
| BARI2 | 0.25 | 0.00 | 0.27 | 0.00 | 0.22 | 0.00 | 0.35 | 0.00 | 0.41 | 0.00 | 0.63 | 0.19 | 0.11 | 0.00 | 0.62 | 0.01 |
| BARI4 | 0.40 | 0.00 | 0.44 | 0.00 | 0.42 | 0.00 | 0.68 | 0.04 | 0.33 | 0.00 | 0.62 | 0.19 | 0.04 | 0.00 | 0.50 | 0.00 |
| DUPI300Q2W | 0.63 | 0.00 | 0.65 | 0.00 | 0.60 | 0.00 | 0.53 | 0.00 | 0.29 | 0.00 | 0.30 | 0.01 | 0.31 | 0.00 | 0.54 | 0.00 |
| LEBRI250Q2W | 0.59 | 0.01 | 0.63 | 0.04 | 0.75 | 0.15 | 0.65 | 0.15 | 0.80 | 0.37 | 0.17 | 0.05 | 0.61 | 0.21 | 0.74 | 0.03 |
| NEMO60Q4W | 0.12 | 0.00 | 0.09 | 0.00 | 0.17 | 0.00 | 0.32 | 0.01 | 0.31 | 0.02 | . | . | 0.73 | 0.34 | 0.99 | 0.96 |
| PBO | 0.01 | 0.00 | 0.05 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.27 | 0.00 | 0.35 | 0.00 | 0.63 | 0.01 | 0.58 | 0.00 |
| TRALO300Q2W | 0.29 | 0.00 | 0.25 | 0.00 | 0.35 | 0.00 | 0.18 | 0.00 | 0.16 | 0.00 | 0.55 | 0.08 | 0.74 | 0.14 | 0.51 | 0.00 |
| UPA15 | 0.83 | 0.00 | 0.86 | 0.00 | 0.82 | 0.00 | 0.78 | 0.01 | 0.54 | 0.00 | 0.65 | 0.07 | 0.35 | 0.00 | 0.31 | 0.00 |
| UPA30 | 0.99 | 0.93 | 0.99 | 0.95 | 0.98 | 0.81 | 0.97 | 0.79 | 0.78 | 0.09 | 0.80 | 0.28 | 0.61 | 0.05 | 0.41 | 0.00 |

b) Association with topical corticosteroids (TCS)

| | EASI 75 | | IGA 0/1 | | EASI 90 | | NRS P | | ANY AE | | UPPER TRACT INFECTION | | SEVERE AE | | WITHDRAWN | |
|----------------|---------|-----------|---------|-----------|---------|-----------|-------|-----------|--------|---------|-----------------------|---------|-----------|---------|-----------|---------|
| | SUCRA | Prob Best | SUCRA | Prob Best | SUCRA | Prob Best | SUCRA | Prob Best | SUCRA | Prob AE | SUCRA | Prob AE | SUCRA | Prob AE | SUCRA | Prob AE |
| ABRO100TCS | 0.57 | 0.01 | 0.55 | 0.00 | . | . | . | . | 0.28 | 0.00 | . | . | 0.60 | 0.01 | 0.36 | 0.00 |
| ABRO200TCS | 0.82 | 0.12 | 0.83 | 0.05 | . | . | . | . | 0.69 | 0.08 | . | . | 0.26 | 0.00 | 0.49 | 0.00 |
| BARI2TCS | 0.28 | 0.00 | 0.24 | 0.00 | 0.25 | 0.00 | 0.36 | 0.01 | 0.72 | 0.02 | 0.75 | 0.33 | 0.40 | 0.00 | 0.39 | 0.00 |
| BARI4TCS | 0.39 | 0.00 | 0.42 | 0.00 | 0.46 | 0.00 | 0.58 | 0.05 | 0.94 | 0.62 | 0.69 | 0.19 | 0.80 | 0.01 | 0.73 | 0.01 |
| DUPI300Q2WTCS | 0.73 | 0.02 | 0.66 | 0.00 | 0.77 | 0.06 | 0.68 | 0.09 | 0.32 | 0.00 | 0.51 | 0.24 | 0.43 | 0.00 | 0.29 | 0.00 |
| NEMO30Q4WTCS | . | . | . | . | . | . | . | . | 0.61 | 0.19 | . | . | 0.99 | 0.97 | 0.99 | 0.97 |
| PBOTCS | 0.04 | 0.00 | 0.02 | 0.00 | 0.02 | 0.00 | 0.03 | 0.00 | 0.23 | 0.00 | 0.46 | 0.01 | 0.61 | 0.00 | 0.59 | 0.00 |
| TEZE280Q2WTCS | 0.14 | 0.00 | 0.25 | 0.00 | . | . | . | . | 0.25 | 0.02 | 0.07 | 0.00 | 0.44 | 0.00 | 0.40 | 0.00 |
| TRALO300Q2WTCS | 0.34 | 0.00 | 0.26 | 0.00 | 0.31 | 0.00 | 0.20 | 0.01 | 0.37 | 0.01 | 0.55 | 0.09 | 0.14 | 0.00 | 0.38 | 0.00 |
| UPA15TCS | 0.73 | 0.02 | 0.77 | 0.01 | 0.71 | 0.02 | 0.71 | 0.07 | 0.42 | 0.01 | 0.46 | 0.06 | 0.50 | 0.00 | 0.44 | 0.00 |
| UPA30TCS | 0.97 | 0.83 | 0.99 | 0.94 | 0.98 | 0.92 | 0.93 | 0.77 | 0.67 | 0.06 | 0.51 | 0.08 | 0.32 | 0.00 | 0.44 | 0.00 |

ABRO100: Abrocitinib 100 mg daily; ABRO200: Abrocitinib 200 mg daily; BARI2: Baricitinib 2 mg daily; BARI4: Baricitinib 4 mg daily; DUPI300Q2W: Dupilumab 300 mg every other week; LEBRI250Q2W: Lebrikizumab 250 mg every other week; NEMO60Q4W: Nemolizumab 60 mg every 4 weeks; PBO: Placebo; TEZE280Q2W: Tezepalumab 280 mg every other week;

TRALO300Q2W: Tralokinumab 300 mg every other week; UPA15: Upadacitinib 15 mg daily;
UPA30: Upadacitinib 30 mg daily.

SUCRA: surface under the cumulative ranking curve; prob: probability; NRSP; numerical rating scale for pruritus; AE: adverse event